Kaken Pharmaceutical Co. Overview

  • Year Founded
  • 1948

Year Founded

  • Status
  • Public

  • Employees
  • 1,308

Employees

  • Stock Symbol
  • 4521

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $26.06
  • (As of Friday Closing)

Kaken Pharmaceutical Co. General Information

Description

Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Contact Information

Website
www.kaken.co.jp
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
TKS
Corporate Office
  • 2-28-8 Honkomagome, Bunkyo-ku
  • Tokyo, 113-8650
  • Japan
+81 00-0000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kaken Pharmaceutical Co. Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$26.06 $26.88 $21.03 - $27.08 $987M 37.9M 174K $1.47

Kaken Pharmaceutical Co. Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022
EV 422,281 422,281 534,810 661,940
Revenue 498,609 498,609 539,097 676,801
EBITDA 86,913 86,913 69,396 145,821
Net Income 55,540 55,540 40,183 84,998
Total Assets 1,133,948 1,133,948 1,248,275 1,353,411
Total Debt 25,438 25,438 28,894 31,545
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kaken Pharmaceutical Co. Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kaken Pharmaceutical Co.‘s full profile, request access.

Request a free trial

Kaken Pharmaceutical Co. Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments betwee
Pharmaceuticals
Tokyo, Japan
1,308 As of 2024
00000000

000000

commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit es
000000000000000
Mumbai, India
0000 As of 0000
000.00
000000000 000.00

000 00

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
000000000000000
Mumbai, India
00000 As of 0000
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kaken Pharmaceutical Co. Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Wockhardt Corporation Mumbai, India 0000 000.00 000000000 000.00
Sun Pharmaceutical Industries Corporation Mumbai, India 00000 000000000000
Cipla Corporation Mumbai, India 00000 000000&0
GlaxoSmithKline Consumer Nigeria Corporation Lagos, Nigeria 00 00000000
GSK Corporation Middlesex, United Kingdom 00000 00.000 000000000 00.000
You’re viewing 5 of 17 competitors. Get the full list »

Kaken Pharmaceutical Co. Patents

Kaken Pharmaceutical Co. Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4215183-A1 Diagnosis accuracy improving composition for use in magnification endoscopy or ultra-high magnification endoscopy Pending 17-Sep-2020 0000000000
US-20230329540-A1 Composition for improving diagnostic accuracy for use in magnifying endoscopy and endocytoscopy Pending 17-Sep-2020 0000000000
CA-3174550-A1 Medicament containing sofpironium bromide Pending 03-Mar-2020 00000000
US-20230149349-A1 Medicament containing sofpironium bromide Pending 03-Mar-2020 000000000
JP-2021138690-A Novel pharmaceutical comprising heteroaromatic amide derivative or salt thereof Pending 28-Feb-2020
To view Kaken Pharmaceutical Co.’s complete patent history, request access »

Kaken Pharmaceutical Co. Executive Team (4)

Name Title Board Seat
Hiroyuki Horiuchi Board Member, President, Chief Executive Officer & Representative Director
Tomoyuki Koseki Chief Officer of Marketing & Sales Division
Mitsuru Watanuki Board Member & Executive
Kiyoshi Inoguchi Group Manager, Licesning and Business Development
To view Kaken Pharmaceutical Co.’s complete executive team members history, request access »

Kaken Pharmaceutical Co. Board Members (4)

Name Representing Role Since
00000000 00000000 Kaken Pharmaceutical Co. Board Member, President, Chief Executive Officer & Representative Director 000 0000
000000 000000000 Kaken Pharmaceutical Co. Board Member 000 0000
0000000 00000000 Kaken Pharmaceutical Co. Board Member & Executive 000 0000
00000000 00000 Kaken Pharmaceutical Co. Board Member 000 0000
To view Kaken Pharmaceutical Co.’s complete board members history, request access »

Kaken Pharmaceutical Co. Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kaken Pharmaceutical Co. Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ARTham Therapeutics 13-Dec-2021 0000000000 Drug Discovery
To view Kaken Pharmaceutical Co.’s complete acquisitions history, request access »

Kaken Pharmaceutical Co. ESG

Risk Overview

Risk Rating

Updated April, 11, 2023

28.86 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

00.00

Percentile

To view Kaken Pharmaceutical Co.’s complete esg history, request access »

Kaken Pharmaceutical Co. FAQs

  • When was Kaken Pharmaceutical Co. founded?

    Kaken Pharmaceutical Co. was founded in 1948.

  • Where is Kaken Pharmaceutical Co. headquartered?

    Kaken Pharmaceutical Co. is headquartered in Tokyo, Japan.

  • What is the size of Kaken Pharmaceutical Co.?

    Kaken Pharmaceutical Co. has 1,308 total employees.

  • What industry is Kaken Pharmaceutical Co. in?

    Kaken Pharmaceutical Co.’s primary industry is Pharmaceuticals.

  • Is Kaken Pharmaceutical Co. a private or public company?

    Kaken Pharmaceutical Co. is a Public company.

  • What is Kaken Pharmaceutical Co.’s stock symbol?

    The ticker symbol for Kaken Pharmaceutical Co. is 4521.

  • What is the current stock price of Kaken Pharmaceutical Co.?

    As of 19-Jul-2024 the stock price of Kaken Pharmaceutical Co. is $26.06.

  • What is the current market cap of Kaken Pharmaceutical Co.?

    The current market capitalization of Kaken Pharmaceutical Co. is $987M.

  • What is Kaken Pharmaceutical Co.’s current revenue?

    The trailing twelve month revenue for Kaken Pharmaceutical Co. is $499M.

  • Who are Kaken Pharmaceutical Co.’s competitors?

    Wockhardt, Sun Pharmaceutical Industries, Cipla, GlaxoSmithKline Consumer Nigeria, and GSK are some of the 17 competitors of Kaken Pharmaceutical Co..

  • What is Kaken Pharmaceutical Co.’s annual earnings per share (EPS)?

    Kaken Pharmaceutical Co.’s EPS for 12 months was $1.47.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »